Blood in the Streets: European Bargains

Thesis: World's 4th largest automaker trading at just 3.7x forward earnings with a 10.6% dividend yield. New CEO Carlos Tavares left, turnaround plan underway. US tariff exposure is real (Canada/Mexico plants) but European production provides hedge. At these levels, priced for bankruptcy in a business generating €15B+ FCF. Absurd valuation. The 14-brand portfolio (Peugeot, Fiat, Jeep, Chrysler, Maserati, Alfa Romeo, Citroën, DS, Opel, Vauxhall, RAM, Dodge, Lancia, Abarth) provides unparalleled diversification across segments and geographies. Even a partial recovery to peer valuations (8-10x PE) implies 100%+ upside.

Thesis: Ferrari is the ultimate luxury brand stock — 50%+ EBITDA margins, pricing power that defies inflation, and a 2-year order backlog. Stock hit by luxury sector rotation (China slowdown concerns) but Ferrari's customer base is ultra-wealthy and recession-resistant. First EV model launching 2026. At 28x forward, historically cheap for Ferrari, which has traded at 35-50x in recent years. The brand moat is arguably the strongest in European equities — Birkin bags have competition, but there is only one Prancing Horse.

Thesis: Sanofi hammered after Dupixent patent cliff concerns and consumer health unit (Opella) spinoff. But Dupixent has years of exclusivity left and expanding indications (COPD approval). Pipeline strong with fitusiran (hemophilia) and tolebrutinib (MS). At 8.6x forward with 5%+ yield, this is deep pharma sector value. The Opella spinoff simplifies the story and unlocks capital for pipeline M&A. Sanofi is trading at a bigger discount to European pharma peers (Novo Nordisk, Roche, AstraZeneca) than at any point in the last decade.

Thesis: Bayer's Roundup litigation albatross continues but is being priced in. Crop science division benefits from food security tailwind — global population growth + climate change = structural demand for agricultural solutions. Pharma pipeline has potential with elinzanetant (menopause) and other assets. At 7.5x forward, the stock prices in permanent decline but the sum-of-parts tells a different story. Crop science alone could be worth €30B+ in a separation scenario, and the consumer health division (Aspirin, Claritin) generates steady cash flows. This is a deep contrarian play requiring patience.

Thesis: The ultimate luxury stock, pulled down by broader luxury sector rotation. Hermès has ZERO inventory problem (Birkin bags have multi-year waitlists), 70%+ gross margins, and pricing power that increases with scarcity. China weakness matters less here — Hermès customers are the top 0.1%. Historical dips of >25% are extremely rare and always rewarded. The family-controlled structure (Hermès family owns ~65%) ensures long-term brand stewardship over quarterly earnings management. The leather goods division alone generates margins that most tech companies would envy.

Thesis: World's largest luxury group hit by China consumer slowdown + aspirational luxury normalization. But Louis Vuitton's pricing power remains intact, Dior growing double digits, and wine & spirits bottoming. Bernard Arnault buying shares personally — when the world's 3rd richest person buys his own stock, pay attention. At 18.7x forward, cheapest LVMH has been since 2020. The portfolio of 75 Maisons (Louis Vuitton, Dior, Hennessy, Tiffany, Bulgari, Fendi, Givenchy, Sephora) provides unmatched diversification across luxury segments. Sephora alone is worth €50-60B by some estimates.

Thesis: UBS completed the Credit Suisse integration ahead of schedule, extracting $13B in cost synergies. The world's largest wealth manager with $6T+ AUM. Stock hit by Swiss banking regulation fears and broader European bank selloff. But the franchise value is immense — wealth management is a secular growth business. Ultra-high-net-worth clients don't switch banks easily, creating sticky revenue streams. The combined entity is a global powerhouse in private banking, investment banking, and asset management with unmatched geographic diversification across the Americas, EMEA, and Asia-Pacific.

Thesis: VW trades at just 4.2x forward with 7.1% dividend yield. EV transition costs are real but Porsche, Audi, and Lamborghini provide a profit anchor. Chinese EV competition eating into VW's China market share (was #1). Factory closures in Germany show management is serious about restructuring. At these multiples, you're getting Porsche essentially for free — VW's ~75% stake in Porsche AG is worth roughly €45B, which is nearly the entire VW market cap. The rest of the business (Audi, VW brand, Lamborghini, SEAT/Cupra, Skoda, Bentley, commercial vehicles, financial services) trades at essentially zero implied value.

Thesis: Airbus has a 10-year production backlog worth ~$800B. Boeing's ongoing quality issues (737 MAX, Spirit AeroSystems) shift orders to Airbus. Defense spending surge in Europe (NATO 3% GDP targets) benefits Airbus military division (Eurofighter, A400M, helicopters). Supply chain constraints are the only growth limiter — Airbus wants to deliver more but can't get enough engines (CFM/PW). At 22x forward for a company with decade-long visibility, this is reasonable for an industrial. The space division (Ariane, OneWeb) provides long-term optionality. Airbus is the premier European aerospace play.

Thesis: Barclays 3-year restructuring plan (Project Minerva) showing results — cost-income ratio improving, investment banking outperforming US peers in key segments. UK rate environment supportive for net interest margins. £10B+ shareholder returns announced (dividends + buybacks). At 6.5x forward with improving ROTE (targeting 12%+), this is a UK banking sector re-rating story. The combination of a top-5 global investment bank with a dominant UK retail franchise creates a unique business model in European banking. Unlike pure IB or pure retail banks, Barclays benefits from revenue diversification across cycles.